The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kassberg Thomas Richard since 2006.
This trader's CIK number is 1303811.
At the time of last reporting, Kassberg Thomas Richard was the CBO & EVP of Ultragenyx Pharmaceutical Inc.. (stock ticker symbol RARE).
Also see all insider trading activities at Ultragenyx Pharmaceutical Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RARE | 0 | $0 | 6,028 | $253,778 | 0 | $0 |
| 2024 | RARE | 0 | $0 | 12,520 | $628,995 | 0 | $0 |
| 2023 | RARE | 0 | $0 | 41,846 | $1,396,291 | 39,878 | $273,563 |
| 2022 | RARE | 0 | $0 | 12,655 | $847,084 | 0 | $0 |
| 2021 | RARE | 0 | $0 | 5,221 | $696,188 | 109,734 | $34,017 |
| 2020 | RARE | 0 | $0 | 262 | $23,050 | 0 | $0 |
| 2015 | RARE | 0 | $0 | 26,668 | $1,974,143 | 0 | $0 |
| 2014 | RARE | 1,500 | $31,500 | 33,332 | $1,711,969 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2007 | ITMN | 0 | $0 | 103,936 | $2,654,066 | 149,015 | $1,862,939 |
| 2006 | ITMN | 0 | $0 | 1,474 | $32,516 | 0 | $0 |
1. Ultragenyx Pharmaceutical Inc. (RARE)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-03 | RARE | Sale | 6,028 | 42.10 | 253,778 |
| 2024-03-11 | RARE | Sale | 11,509 | 49.93 | 574,644 |
| 2024-03-01 | RARE | Sale | 1,011 | 53.76 | 54,351 |
| 2023-10-23 | RARE | Option Ex | 39,878 | 6.86 | 273,563 |
| 2023-10-23 | RARE | Sale | 39,878 | 32.78 | 1,307,200 |
| 2023-03-01 | RARE | Sale | 1,968 | 45.27 | 89,091 |
| 2022-03-11 | RARE | Sale | 10,281 | 67.01 | 688,929 |
| 2022-03-01 | RARE | Sale | 2,374 | 66.62 | 158,155 |
| 2021-10-14 | RARE | Sale | 286 | 81.14 | 23,206 |
| 2021-09-30 | RARE | Option Ex | 109,734 | .31 | 34,017 |
| 2021-05-06 | RARE | Sale | 363 | 113.69 | 41,269 |
| 2021-03-01 | RARE | Sale | 4,572 | 138.17 | 631,713 |
| 2020-10-14 | RARE | Sale | 262 | 87.98 | 23,050 |
| 2015-08-12 | RARE | Sale | 3,334 | 109.70 | 365,739 |
| 2015-07-08 | RARE | Sale | 3,334 | 102.12 | 340,468 |
| 2015-06-10 | RARE | Sale | 3,334 | 88.19 | 294,025 |
| 2015-05-13 | RARE | Sale | 3,334 | 72.04 | 240,181 |
| 2015-04-08 | RARE | Sale | 3,333 | 58.02 | 193,380 |
| 2015-03-11 | RARE | Sale | 3,333 | 56.30 | 187,647 |
| 2015-02-11 | RARE | Sale | 3,333 | 54.31 | 181,021 |
| 2015-01-14 | RARE | Sale | 3,333 | 51.51 | 171,682 |
| 2014-12-10 | RARE | Sale | 3,333 | 40.22 | 134,053 |
| 2014-11-12 | RARE | Sale | 3,333 | 41.85 | 139,486 |
| 2014-10-08 | RARE | Sale | 3,333 | 53.26 | 177,515 |
| 2014-09-10 | RARE | Sale | 3,333 | 54.82 | 182,715 |
| 2014-09-03 | RARE | Sale | 10,000 | 55.00 | 550,000 |
| 2014-09-02 | RARE | Sale | 10,000 | 52.82 | 528,200 |
| 2014-01-30 | RARE | Buy | 1,500 | 21.00 | 31,500 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2007-12-28 | ITMN | Sale | 9,375 | 13.45 | 126,093 |
| 2007-12-28 | ITMN | Option Ex | 9,375 | 10.11 | 94,781 |
| 2007-10-10 | ITMN | Sale | 4,289 | 19.31 | 82,812 |
| 2007-10-01 | ITMN | Option Ex | 24,684 | 12.36 | 305,094 |
| 2007-10-01 | ITMN | Option Ex | 24,684 | 12.36 | 305,094 |
| 2007-07-09 | ITMN | Option Ex | 40,763 | 11.98 | 488,340 |
| 2007-07-10 | ITMN | Option Ex | 12,900 | 11.98 | 154,542 |
| 2007-07-09 | ITMN | Sale | 40,763 | 27.27 | 1,111,729 |
| 2007-07-10 | ITMN | Sale | 12,900 | 27.24 | 351,396 |
| 2007-07-06 | ITMN | Option Ex | 36,609 | 14.07 | 515,088 |
| 2007-07-06 | ITMN | Sale | 36,609 | 26.82 | 982,036 |
| 2006-11-01 | ITMN | Sale | 1,474 | 22.06 | 32,516 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kassberg Thomas Richard (CBO & EVP of Ultragenyx Pharmaceutical Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.